Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Mark S. Lesney

    News

    Patients with CLL have significantly reduced response to COVID-19 vaccine 

    Author:
    Mark S. Lesney
    Phd
    Publish date: May 16, 2021

    Less than half of CLL patients had an antibody-mediated response to the Pfizer vaccine in a study.

    • Read More

    News

    Combo drug improves survival in older patients with high-risk/secondary AML

    Author:
    Mark S. Lesney
    Publish date: June 26, 2020

    CPX-351 therapy was tied to long-term remission and survival in older patients with newly diagnosed high-risk or...

    • Read More

    News

    FDA approves twice-daily formulation of key thalassemia drug

    Author:
    Mark S. Lesney
    Publish date: May 22, 2020

    The new formulation of twice-a-day Ferriprox 1,000 mg oral tablets eliminates the midday dose.

    • Read More

    News

    Vaccination regimen effective in preventing pneumonia in MM patients

    Author:
    Mark S. Lesney
    Publish date: May 21, 2020

    Vaccination was effective despite the expected decrease in immunological response during target and...

    • Read More

    News

    Race and location appear to play a role in the incidence of CLL and DLBCL

    Author:
    Mark S. Lesney
    Publish date: May 20, 2020

    Urban non Hispanic blacks and Hispanics have an increased incidence of CLL, DLBCL, respectively vs. rural....

    • Read More

    News

    Secondary acute lymphoblastic leukemia more lethal than de novo

    Author:
    Mark S. Lesney
    Publish date: May 14, 2020

    Adult patients with secondary ALL had poorer overall survival than de novo ALL patients.

    • Read More

    News

    Protective levels of vitamin D achievable in SCD with oral supplementation

    Author:
    Mark S. Lesney
    Publish date: May 12, 2020

    Vitamin D3 prophylaxis is a safe practice in sickle cell disease, and it is important to start this prophylactic treatment when the child is an...

    • Read More

    News

    DLBCL patients at academic centers had significantly better survival

    Author:
    Mark S. Lesney
    Publish date: May 11, 2020

    Researchers suggested that academic centers might provide increased access to clinical trials, improved physician expertise, improved treatment...

    • Read More

    News

    Interleukin-27 increased cytotoxic effects of bone marrow NK cells in CLL

    Author:
    Mark S. Lesney
    Publish date: May 6, 2020

    Interleukin-27 was able to increase cytotoxic effects of bone marrow natural killer cells in chronic lymphocytic leukemia (CLL).

    • Read More

    News

    SARS-CoV-2 present significantly longer in stool than in respiratory, serum samples

    Author:
    Mark S. Lesney
    Publish date: April 27, 2020

    SARS-CoV-2 is present significantly longer in samples from severe COVID-19 patients than from patients with mild...

    • Read More

    News

    Combo therapy with melflufen promising in small r/r multiple myeloma study

    Author:
    Mark S. Lesney
    Publish date: April 23, 2020

    Melflufen plus dexamethasone showed activity in patients with relapsed/refractory multiple myeloma.

    • Read More

    News

    REACH2: Ruxolitinib outperformed control treatment for refractory acute GVHD

    Author:
    Mark S. Lesney
    Publish date: April 22, 2020

    Ruxolitinib was significantly more effective against acute graft-versus-host disease but produced more thrombocytopenia than did control treatment...

    • Read More

    News

    Five prognostic indexes come up short for planning early CLL treatment

    Author:
    Mark S. Lesney
    Publish date: April 22, 2020

    None of the indexes was able to predict with total precision the clinical evolution of Binet A chronic...

    • Read More

    News

    EHA and TIF explore how COVID-19 is affecting thalassemia and SCD patients

    Author:
    Mark S. Lesney
    Publish date: April 20, 2020

    Thalassemia patients appeared to fare relatively well after COVID-19 diagnosis in anecdotal series reports from...

    • Read More

    News

    CLAM trial regimen shown safe, effective for r/r AML

    Author:
    Mark S. Lesney
    Publish date: April 17, 2020

    High response rates and effective bridge to transplant shown.

    • Read More

    Pages

    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • …
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery